GTB-3650 Tri-Specific Killer Engager (TriKE®)
HM2023-05: GTB-3650 (Anti-CD16/IL-15/Anti-CD33) Tri-Specific Killer Engager (TriKE®) for the Treatment of High Risk Myelodysplastic Syndromes (MDS) and Refractory/Relapsed Acute Myeloid Leukemia (AML)
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 1
- Enrollment
- 45 patients (estimated)
- Sponsors
- University of Minnesota - Masonic Cancer Center
- Tags
- CD16, CD33, Interleukin 15 (IL-15)
- Trial Type
- Treatment
- Last Update
- 1 month ago
- SparkCures ID
- 2021
- NCT Identifier
- NCT06594445
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.